HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sansalvamide A

a cyclic depsipeptide; inhibits poxvirus topoisomerase; structure in first source

Also Known As:

San A-amide

Networked: 14 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - sansalvamide A: 14
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - sansalvamide A: 14

Experts

1.	McAlpine, Shelli R: 8 articles (01/2010 - 08/2005)
2.	Pan, Po-Shen: 5 articles (08/2009 - 08/2005)
3.	McGuire, Kathleen L: 5 articles (02/2008 - 03/2006)
4.	Otrubova, Katerina: 4 articles (02/2008 - 03/2006)
5.	Li, Yumin: 2 articles (01/2022 - 07/2018)
6.	Wang, Xiaohui: 2 articles (01/2022 - 07/2018)
7.	Zhang, Jun: 2 articles (01/2022 - 07/2018)
8.	Liu, Shouxin: 2 articles (04/2018 - 07/2014)
9.	Ardi, Veronica C: 2 articles (01/2010 - 08/2009)
10.	Silverman, Richard B: 2 articles (01/2010 - 02/2006)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 09/15/2007 - "Identification of Sansalvamide a analog potent against pancreatic cancer cell lines." 07/01/2018 - "In this study, we radiolabeled a dimeric Sansalvamide A derivative (Di-San A1) with 64Cu, and evaluated the feasibility of using 64Cu-Di-San A1 for PET imaging of Hsp90 expression in a mouse model of pancreatic cancer. " 01/01/2010 - "We previously observed antiproliferative effects in a series of sansalvamide A analogs in pancreatic cancer cells, one of which was further evaluated in this study. " 08/15/2009 - "A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines." 07/01/2018 - "PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide."
2.	Colonic Neoplasms (Colon Cancer) 05/03/2007 - "We have identified five derivatives of the natural product sansalvamide A that are potent against multiple drug-resistant colon cancer cell lines. " 02/14/2008 - "Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines." 02/14/2008 - "Thus, we have established sansalvamide A as an excellent lead for treating multiple drug-resistant colon cancers." 05/03/2007 - "Thus, we have established sansalvamide A as a privileged structure for treating multiple drug-resistant colon cancers." 08/15/2006 - "We report the synthesis of thirty-six Sansalvamide A derivatives, and their biological activity against colon cancer HT-29 cell line, a microsatellite stable (MSS) colon cancer cell-line. "
3.	Experimental Melanoma 07/01/2014 - "In the present study, H-10 (molecular formula, C38H55N5O6; molecular weight, 677.8732), a novel sansalvamide A derivative, demonstrated an inhibitory effect on the proliferation of murine melanoma B16 cells. "
4.	Neoplasms (Cancer) 04/01/2018 - "The effect of a novel sansalvamide A analogue named LY-15 on the growth and induction of apoptosis in B16 cancer cells was investigated in vitro. " 01/01/2010 - "Herein we show that San A-amide, a structurally unique molecule, influences a subset of cancer-related pathways involving Hsp90. " 04/01/2018 - "In addition, sansalvamide A analogue LY-15 may a significant therapeutic target for the treatment of malignant melanoma cancer." 01/01/2010 - "This unique mechanism suggests that San A-amide is a potential tool for studying C-terminal binding proteins of Hsp90 as well as a promising lead in the development of new cancer therapeutics."
5.	Melanoma (Melanoma, Malignant) 04/01/2018 - "In addition, sansalvamide A analogue LY-15 may a significant therapeutic target for the treatment of malignant melanoma cancer."

Related Drugs and Biologics

1.	Carrier Proteins (Binding Protein)

Related Therapies and Procedures

1.	Therapeutics